Berenberg keeps EUR 3.60 target for Evotec stock

Published on 10/20/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec's nine-month revenue reached EUR 465.0 million in 2026. Evotec stock costs EUR 2.63 on October 20, 2026 versus Xetra close EUR 2.63.

Analyst target and reporting dates

Berenberg maintained its EUR 3.60 target for Evotec on October 16, 2026.
Evotec expects EUR 465.0 million in revenue for the first nine months of 2026.
Evotec stock trades at EUR 2.63 at 10:00 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.00 percent versus the Xetra close of October 19, 2026.
Evotec will publish third-quarter and nine-month results on November 5, 2026.

3D-Architekturvisualisierung eines modernen Glas-Forschungscampus mit begrüntem Innenhof — Architektur-Render eines modernen Forschungscampus veranschaulicht den Biotech-Standort von Evotec SE, ISIN DE0005664809, glasklar gestaltet, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) trades at EUR 2.63 at Lang & Schwarz on October 20, 2026, at 10:00 a.m. CEST, unchanged against the Xetra close of October 19, 2026. Markets Insider reported on October 16, 2026, that Berenberg maintained a Hold rating and a EUR 3.60 price target. The target is 36.88 percent above the Lang & Schwarz price.

What changed in October

The latest analyst view follows a more substantive company update. In its October 13, 2026 release, Evotec said preliminary revenue for the first nine months of 2026 should reach EUR 465.0 million, while adjusted EBITDA was expected at a loss of EUR 42.8 million. Les Echos carried the company announcement, which said the preliminary figures were above market expectations.

Evotec also reaffirmed full-year 2026 revenue guidance of EUR 570 million to EUR 610 million. Adjusted EBITDA guidance remained a loss of EUR 70 million to EUR 105 million, showing that the revenue improvement has not yet translated into positive adjusted operating earnings.

Three dated signals for investors

On October 13, 2026, Evotec set preliminary nine-month revenue at EUR 465.0 million. On October 15, 2026, the company announced Joanna Holbrook as chief scientific officer, effective November 1, 2026, according to MarketScreener. On October 16, 2026, Berenberg kept its EUR 3.60 target, according to Markets Insider.

Which dates come next

Holbrook's appointment takes effect on November 1, 2026, and Evotec is scheduled to publish third-quarter and nine-month results on November 5, 2026. The reporting date is stated in the October 13 company announcement.

Stock price and valuation context

Evotec's EUR 2.63 quote at Lang & Schwarz was unchanged from the EUR 2.63 Xetra close dated October 19, 2026. The stock's reported 52-week range is EUR 2.41 to EUR 7.30, placing the current euro quote EUR 0.22 above the low and EUR 4.67 below the high. Market capitalization was EUR 471.3 million as of October 20, 2026.

Evotec was trading at EUR 2.63 at Lang & Schwarz on October 20, 2026, at 10:00 a.m. CEST, 0.00 percent versus the Xetra close of October 19, 2026 (EUR 2.63). The further course of trading is shown by the continuously updated real-time quote of Evotec stock.